Highlighted Issues

The Issues content focuses on current, important and relevant state, national and world issues and NAMSDL’s intent to synthesize and evaluate information and present it in an informed manner.

 

This report describes the preliminary recommendations of the President’s Commission on Combating Addiction and the Opioid Crisis. Read more »

Addiction Opioid President’s Commission

 

This document provides a summary of legislation and regulation introduced during calendar year 2017 that pertains to novel psychoactive substances (“NPS”) and controlled substance analogues. The summary is divided into three categories of legislation/regulation: enacted, currently pending-but-not-yet-enacted; and proposed-but-not-enacted. Read more »

analog analogue bill status update cannabinoid cathinone designer drug fentanyl new psychoactive substance novel psychoactive substance nps schedule synthetic drug

 

This document highlights the latest trends in 2017 PMP bills and how state legislators are shaping the future of PMPs. Read more »

bills highlights PDMPs PMPs prescription drug monitoring programs prescription monitoring programs summaries

 

This document describes the similarities and differences among state mandated PMP use provisions for prescribers. It reflects the increasing refinements by state officials who are trying to use the mandate to increase PMP use by health care professionals. Read more »

mandated PDMP access mandated PDMP use mandated PMP access mandated PMP use required PMP use required PDMP use

 

This document is a product of NAMSDL’s extensive review and analysis of current state laws addressing novel psychoactive substances (“NPS”) and controlled substance analogues. On a state-by-state basis, NAMSDL lays out laws pertaining to many issues, including: expeditious scheduling, definition/treatment of analogues, fentanyl-specific provisions and penalties for violations. Read more »

analog analogue cannabinoid cathinone designer drug fentanyl new psychoactive substance novel psychoactive substance nps schedule synthetic drug

1 2 3 4 5 6 7 NEXT